In this issue:
Rechallenging RAS/BRAF wt mCRC resistant to cetuximab & irinotecan
Pertuzumab + trastuzumab in HER2-amplified mCRC
Antineoplastic therapy is expensive for payers and society
Familial CRC risk in half siblings and siblings
Obesity increases risk of early-onset CRC in women
Nivolumab + SOX/CapeOX promising in GOJ carcinoma
Longer-duration adjuvant imatinib in resected primary GIST
Predicting survival with 2L CTX in BTC
Regorafenib in CTX-refractory, advanced/metastatic BTC
DNA variation affects survival in CRC
Please login below to download this issue (PDF)